INmune Bio Inc. (INMB) Discusses XPro1595 Phase II MINDFuL Results and Registrational Strategy in Alzheimer's Disease Transcript [Seeking Alpha]
INmune Bio Inc. - Common stock (INMB)
Company Research
Source: Seeking Alpha
Company Participants David Moss - President, CEO, Treasurer, Secretary & Director Christopher Barnum Conference Call Participants Michael Woodward Sharon Cohen - Toronto Memory Program Presentation David Moss President, CEO, Treasurer, Secretary & Director Good morning, everyone. I'm David Moss, CEO of INmune Bio. Thank you for joining us today. INmune Bio is a clinical stage biotechnology company developing therapies that target neuroinflammation in neurodegenerative disease. Our lead program, XPro1595 is a first-in-class selective soluble TNF inhibitor. It works by blocking the form of TNF that drives pathology while preserving the form that supports normal immune function. That distinction is central to everything you'll hear today. The objective of today's webinar is straightforward to demonstrate how clinical results of our Phase II MINDFuL trial directly forge the blueprint for our registration program. Following a very productive end of Phase II meeting wit
Show less
Read more
Impact Snapshot
Event Time:
INMB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INMB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INMB alerts
High impacting INmune Bio Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
INMB
News
- INmune Bio Inc. (INMB) Discusses MissionEB Phase III Trial and CORDStrom as a Disease-Modifying Therapy for RDEB Transcript [Seeking Alpha]Seeking Alpha
- INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer's Webinar [Yahoo! Finance]Yahoo! Finance
- INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer’s WebinarGlobeNewswire
- INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEBGlobeNewswire
- INmune Bio submits pre-submission package for CORDStrom with MHRA [Yahoo! Finance]Yahoo! Finance
INMB
Earnings
- 10/30/25 - Beat
INMB
Sec Filings
- 2/27/26 - Form 8-K
- 2/23/26 - Form 8-K
- 2/19/26 - Form 8-K
- INMB's page on the SEC website